Top 3 Health Care Stocks That May Collapse This Month
Three healthcare stocks flash overbought warnings: Surgery Partners (RSI 89.5), Mentari Therapeutics (85.2), and Xeris Biopharma (71.3).

Last updated: 2026-11-18 21:15:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Mentari Therapeutics, Inc. (MTRI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.32, with a market capitalization of $1.16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.20 to $20.00. This page covers its latest market performance, valuation, price trends and company information.
$1.16B | |
$18.11 | |
$18.87 | |
$14.70 | |
$17.50 | |
215.01K | |
73.17K | |
-- | |
$20.00 | |
$12.20 | |
-- | |
-- |
Mentari Therapeutics, Inc. (MTRI) is trading at $15.18 in after-hours trading as of 2026-11-18 21:11:00, down 0.95% ($0.15) from the regular-session close of $15.32.
After-hours trading shows how investors are pricing MTRI after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Mentari Therapeutics, Inc. (MTRI) moved from $16.00 to $15.32, representing a decline of 4.24% ($0.68).
The stock traded between $12.20 and $20.00 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 73.17 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40.0%
MTRI is currently trading at $15.32, placing it 40.0% of the way from its 52-week low of $12.20 to its 52-week high of $20.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Mentari Therapeutics, Inc. and MTRI stock.
Three healthcare stocks flash overbought warnings: Surgery Partners (RSI 89.5), Mentari Therapeutics (85.2), and Xeris Biopharma (71.3).
Analysts initiated coverage on UCTT, DNLI, HAE, MTRI and ADI, assigning ratings from Equal-Weight to Buy and targets of $33-$505.
Wedbush analyst Laura Chico initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Outperform rating and announces Price Target of $33.
Eligible investors can buy real shares of Mentari Therapeutics, Inc. (MTRI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MTRI, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MTRI shares and USD.
MTRI Shares to USD
1.00 MTRI shares = 15.321 USD
Calculations are estimates based on the latest available price and are for reference only.